Successful scale-up of PL-14 production paves the way for 2026 clinical trials and future commercial readiness.
Polyrizon (PLRZ), a biotechnology company developing novel intranasal products based on its proprietary Capture & Contain (C&C) platform, announced a significant manufacturing breakthrough as it completed a major scale-up milestone for its PL-14 nasal spray formulation. This achievement marks an essential step in preparing for upcoming clinical trials and positions the company closer to eventual commercialization.
Working alongside its contract development and manufacturing organization (CDMO) partner, Polyrizon successfully advanced from small-batch laboratory production to a larger, controlled manufacturing run designed to validate the core production parameters of PL-14. The scale-up confirmed that the formulation can be produced reliably at higher volumes while maintaining stringent quality standards. This batch will support the clinical trial material required for Polyrizon’s planned 2026 clinical program, ensuring compliance with both U.S. and European regulatory expectations.
“This successful batch production is a testament to the strength of our C&C technology and the expertise of our CDMO partner,” said Tomer Izraeli, Polyrizon’s CEO. “The process validated our manufacturing strategy. With this batch in hand, we are energized and prepared to advance into next batches towards clinical trial material manufacturing, which brings us one step closer to addressing unmet needs in the nasal spray market.”
PL-14 represents Polyrizon’s leading innovation — a fast-acting, moisturizing intranasal spray designed to form a protective bio-adhesive barrier inside the nasal cavity. This barrier traps, isolates, and neutralizes airborne allergens before they can reach the mucosal lining. Unlike traditional pharmacological treatments, PL-14 offers an extended-duration, non-drug solution tailored for individuals exposed to high concentrations of environmental allergens.
As Polyrizon moves toward clinical development, the company’s successful manufacturing scale-up underscores its readiness to advance a new category of intranasal protection aimed at improving the daily lives of allergy sufferers worldwide.
You might like the article:Nvidia Invests $2 Billion in Synopsys to Accelerate the Future of AI and Engineering
